Skip to content
EntityQ418702· pop 19· linked from 384 articles

Basiliximab

Sign in to save

Also known as CHI621, SDZ-CHI-621, CHI-621, chimeric mouse-human antiCD25, Ig gamma-1 chain C region

Protein

Key facts

Drug.Verifiedfields
changed
Drug.verifiedrevid
459525440
Drug.type
mab
Drug.mab_type
mab
Drug.source
xi/o
Drug.target
CD25
Drug.tradename
Simulect
Drug.MedlinePlus
a612013
Drug.licence_EU
yes
Drug.DailyMedID
Basiliximab
Drug.pregnancy_AU
D
Drug.routes_of_administration
Intravenous
Drug.class
Immunosuppressants
Drug.ATC_prefix
L04
Drug.ATC_suffix
AC02
Drug.legal_US
Rx-only
Drug.legal_EU
Rx-only
Drug.legal_status
Rx-only

via Wikipedia infobox

Chemical data

Drug data · ChEMBL

Max clinical phase
Approved
Molecule type
Antibody
First approval
1998
Admin. routes
parenteral
Indications
neoplasm, ulcerative colitis, immune system disease, chronic kidney disease

via ChEMBL · EBI

Wikidata facts

Has use
medication
Show 6 more facts
defined daily dose
40
World Health Organisation international non-proprietary name
basiliximab
subject has role
monoclonal antibody
chemical formula
C₆₃₇₈H₉₈₄₄N₁₆₉₈O₁₉₉₇S₄₈
has characteristic
biopharmaceutical
legal status (medicine)
boxed warning
Sources (7)

via Wikidata · CC0

Article · Deutsch

Basiliximab ist ein chimärer monoklonaler Antikörper gegen den Interleukin-2-Rezeptor (CD25), der therapeutisch zur Prävention akuter Abstoßungsreaktionen nach Nieren- und Lebertransplantationen eingesetzt wird.

Abstract from DBpedia / Wikipedia · CC BY-SA